Reactions of clinical neuropsychologists to the Alzheimer's Association workgroup's draft diagnostic and staging criteria for Alzheimer's disease

被引:0
作者
Kiselica, Andrew M. [1 ]
Atkins, Kelly J. [2 ,3 ]
Han, S. Duke [4 ]
Diaz-Orueta, Unai [5 ]
Gogniat, Marissa A. [6 ]
Blanco-Campal, Alberto [7 ,8 ]
Hermann, Greta [9 ]
Duff, Kevin [10 ]
机构
[1] Univ Georgia, Inst Gerontol, Athens, GA 30602 USA
[2] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA
[3] Monash Univ, Sch Psychol, Melbourne, Australia
[4] Univ Southern Calif, Dept Psychol, Los Angeles, CA USA
[5] Maynooth Univ, Dept Psychol, Maynooth, Ireland
[6] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA USA
[7] Mental Hlth Serv Older Adult, Hlth Serv Execut, Limerick, Ireland
[8] Mater Misericordiae Univ Hosp, Dublin Neurol Inst, Dublin, Ireland
[9] Univ Missouri, Dept Hlth Psychol, Columbia, MO USA
[10] Oregon Hlth & Sci Univ, Oregon Alzheimers Dis Res Ctr, Dept Neurol, Portland, OR USA
关键词
Alzheimer's disease; biomarkers; clinical syndrome; diagnostic criteria; neuropsychology; staging; MILD COGNITIVE IMPAIRMENT; NATIONAL INSTITUTE; RECOMMENDATIONS; BIOMARKERS; GUIDELINES;
D O I
10.1177/13872877241292089
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: An Alzheimer's Association (AA) workgroup published criteria for the diagnosis and staging of Alzheimer's disease (AD). To date, there have not been empirical investigations of professionals' opinions regarding the AA criteria for AD. Objective: Our goal was to survey clinical neuropsychologists with expertise in dementia about these criteria. Methods: Participants were recruited from a professional interest group of neuropsychologists focused on dementia. They rated their agreement with 15 statements about the AA draft criteria for AD prior to publication of the final version. The 15 statements were rated on a 4-point Likert scale ranging from 1 = Strongly Disagree to 4 = Strongly Agree. Results: Sixty-one respondents provided analyzable data. When all 15 statements were coded such that higher values suggested more concern about the recommendations, the mean rating was 3.12 (SD = 0.36), suggesting that overall respondents had modest concerns about the recommendations. The statements that yielded the most concern focused on barriers to the implementation of the recommendations, including a lack of healthcare resources and costs of biomarker testing. Conversely, participants were equivocal about the criteria being a positive step forward and had mixed opinions about the applicability of these criteria to diverse groups. Conclusions: Opinions of neuropsychologists suggest the need for important revisions or additions to the AA criteria for AD, including a clearer statement of purpose and more guidance on practical implementation.
引用
收藏
页码:877 / 884
页数:8
相关论文
共 50 条
  • [41] Progress in Alzheimer's disease
    Galimberti, Daniela
    Scarpini, Elio
    JOURNAL OF NEUROLOGY, 2012, 259 (02) : 201 - 211
  • [43] The New Criteria for Alzheimer's Disease - Implications for Geriatricians
    Molin, Pierre
    Rockwood, Kenneth
    CANADIAN GERIATRICS JOURNAL, 2016, 19 (02) : 66 - 73
  • [44] Biomarkers in Alzheimer's disease
    Garcia-Ribas, Guillermo
    Lopez-Sendon Moreno, Jose Luis
    Garcia-Caldentey, Juan
    REVISTA DE NEUROLOGIA, 2014, 58 (07) : 308 - 317
  • [45] Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations
    Petersen, Ronald C.
    Graf, Ana
    Brady, Chris
    De Santi, Susan
    Florian, Hana
    Landen, Jaren
    Pontecorvo, Mike
    Randolph, Christopher
    Sink, Kaycee M.
    Carrillo, Maria C.
    Weber, Christopher J.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2023, 9 (04)
  • [46] The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study
    Bosco, Paolo
    Redolfi, Alberto
    Bocchetta, Martina
    Ferrari, Clarissa
    Mega, Anna
    Galluzzi, Samantha
    Austin, Mark
    Chincarini, Andrea
    Collins, D. Louis
    Duchesne, Simon
    Marechal, Benedicte
    Roche, Alexis
    Sensi, Francesco
    Wolz, Robin
    Alegret, Montserrat
    Assal, Frederic
    Balasa, Mircea
    Bastin, Christine
    Bougea, Anastasia
    Emek-Savas, Derya Durusu
    Engelborghs, Sebastiaan
    Grimmer, Timo
    Grosu, Galina
    Kramberger, Milica G.
    Lawlor, Brian
    Stojmenovic, Gorana Mandic
    Marinescu, Mihaela
    Mecocci, Patrizia
    Molinuevo, Jose Luis
    Morais, Ricardo
    Niemantsverdriet, Ellis
    Nobili, Flavio
    Ntovas, Konstantinos
    O'Dwyer, Sarah
    Paraskevas, George P.
    Pelini, Luca
    Picco, Agnese
    Salmon, Eric
    Santana, Isabel
    Sotolongo-Grau, Oscar
    Spiru, Luiza
    Stefanova, Elka
    Popovic, Katarina Surlan
    Tsolaki, Magda
    Yener, Gorsev G.
    Zekry, Dina
    Frisoni, Giovanni B.
    ALZHEIMERS & DEMENTIA, 2017, 13 (09) : 1013 - 1023
  • [47] Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment
    Herukka, Sanna-Kaisa
    Simonsen, Anja Hviid
    Andreasen, Niels
    Baldeiras, Ines
    Bjerke, Maria
    Blennow, Kaj
    Engelborghs, Sebastiaan
    Frisoni, Giovanni B.
    Gabryelewicz, Tomasz
    Galluzzi, Samantha
    Handels, Ron
    Kramberger, Milica G.
    Kulczynska, Agnieszka
    Luis Molinuevo, Jose
    Mroczko, Barbara
    Nordberg, Agneta
    Oliveira, Catarina Resende
    Otto, Markus
    Rinne, Juha O.
    Rot, Uros
    Saka, Esen
    Soininen, Hilkka
    Struyfs, Hanne
    Suardi, Silvia
    Visser, Pieter Jelle
    Winblad, Bengt
    Zetterberg, Henrik
    Waldemar, Gunhild
    ALZHEIMERS & DEMENTIA, 2017, 13 (03) : 285 - 295
  • [48] Alzheimer's disease CSF biomarkers: clinical indications and rational use
    Niemantsverdriet, Ellis
    Valckx, Sara
    Bjerke, Maria
    Engelborghs, Sebastiaan
    ACTA NEUROLOGICA BELGICA, 2017, 117 (03) : 591 - 602
  • [49] The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
    Luis Molinuevo, Jose
    Blennow, Kaj
    Dubois, Bruno
    Engelborghs, Sebastiaan
    Lewczuk, Piotr
    Perret-Liaudet, Armand
    Teunissen, Charlotte E.
    Parnetti, Lucilla
    ALZHEIMERS & DEMENTIA, 2014, 10 (06) : 808 - 817
  • [50] Neurophysiological trajectories in Alzheimer's disease progression
    Kudo, Kiwamu
    Ranasinghe, Kamalini G.
    Morise, Hirofumi
    Syed, Faatimah
    Sekihara, Kensuke
    Rankin, Katherine P.
    Miller, Bruce L.
    Kramer, Joel H.
    Rabinovici, Gil D.
    Vossel, Keith
    Kirsch, Heidi E.
    Nagarajan, Srikantan S.
    ELIFE, 2024, 12